Acute lymphoblastic leukaemia develops in both children and adults, with a peak incidence
between 1 year and 4 years. Most acute lymphoblastic leukaemia arises in healthy …

Acute lymphoblastic leukemia (ALL) is the second most common acute leukemia in adults,
with an incidence of over 6500 cases per year in the United States alone. The hallmark of …

The NCCN Guidelines for Acute Lymphoblastic Leukemia (ALL) focus on the classification of
ALL subtypes based on immunophenotype and cytogenetic/molecular markers; risk …

Retrospective studies have suggested that older adolescents and young adults (AYAs) with
acute lymphoblastic leukemia (ALL) have better survival rates when treated using a pediatric …

Background Treatment outcomes among survivors of cancer diagnosed during adolescence
and early young adulthood have not been characterised independently of survivors of …

Background In estimating the global burden of cancer, adolescents and young adults with
cancer are often overlooked, despite being a distinct subgroup with unique epidemiology …

Purpose To review the impact of collaborative studies on advances in the biology and
treatment of acute lymphoblastic leukemia (ALL) in children and adolescents. Methods A …

Fewer than 1 in 20 adult cancer patients enroll in cancer clinical trials. But although barriers
to trial participation have been the subject of frequent study, the rate of trial participation has …

Adults with acute lymphoblastic leukemia (ALL) do worse than children. From 7/2008 to
12/2014, Nordic and Baltic centers treated 1509 consecutive patients aged 1–45 years with …

Acute lymphoblastic leukaemia occurs in both children and adults but its incidence peaks
between 2 and 5 years of age. Causation is multifactorial and exogenous or endogenous …